AstraZeneca invests in the UK
AstraZeneca is investing US$109m (€96m) in new laboratories and office accommodation at its major r&d site at Alderley Park, Cheshire, UK. Cancer research and enabling technologies will be AstraZeneca's major growth areas at the site, together with research into cardiovascular disease and inflammatory conditions such as arthritis. The investment includes a DNA archive and genotyping centre and a protein and cell production facility.